Pharmaceutical

Debiopharm, SunRock sign agreement for cancer ADCs

Debiopharm and SunRock Biopharma have signed an agreement to advance the development of specifically targeted ADCs for hard-to-treat cancers.

Sep 23, 2023 - 20:00
Debiopharm, SunRock sign agreement for cancer ADCs
Debiopharm and SunRock Biopharma have signed an agreement to advance the development of specifically targeted ADCs for hard-to-treat cancers.
Read the original article

Tags:

Previous Article

Glenmark Pharma to divest 75% stake in life sciences unit for $680m

Next Article

Chromosome-scale genome sequence of Suaeda glauca sheds light on salt stress tol...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Rocket Pharmaceuticals’ RP-A601 receives FDA designations

Rocket Pharmaceuticals’ RP-A601 receives FDA designations

Jun 9, 2023

CTS Europe: The roadmap for generative AI in the pharma industry

CTS Europe: The roadmap for generative AI in the pharma...

Mar 7, 2024

Tourmaline shifts focus to developing anti-IL6 antibody following merger

Tourmaline shifts focus to developing anti-IL6 antibody...

Oct 21, 2023